11 Feb 2026 GLP-1 RA and SGLT2i in type 2 diabetes
This live webinar has already taken place. Scroll down to view the video recording. You can view or download the presenter’s slide deck by clicking on the DOWNLOAD button.
=====
This TI Best Evidence webinar was an encore presentation, originally delivered as part of the TI Best Evidence for Clinicians 2025 Annual Course on Friday, November 28, 2025 by Dr. Guillaume Grenet, MD, PhD, endocrinologist from Lyon, France and Research Associate with the UBC Therapeutics Initiative and the Cochrane Hypertension Group in Vancouver, BC. This presentation summarized the evidence about glucagon-like peptide-1 receptor agonist (GLP-1 RA) and sodium-glucose cotransporter-2 (SGLT2) inhibitors for cardiovascular prevention in type 2 diabetes. The 30-minute presentation was followed by a 30-minute interactive questions & answers session with Dr. Grenet.
—
TITLE: GLP-1 RA and SGLT2i in type 2 diabetes
WHEN: 12:00 – 1:00 PM PST on Wednesday, February 11th, 2026 [convert to your local time]
WHERE: This was a free virtual event.
SPEAKER: Dr. Guillaume Grenet, MD, PhD, endocrinologist from Lyon, France, and Research Associate with the UBC Therapeutics Initiative and the Cochrane Hypertension Group in Vancouver, BC.
LEARNING OBJECTIVE (by the end of this session, participants will be able to):
- communicate the uncertainty around the cardiovascular effect of GLP-1 RA.
About the topic: Glucagon-like peptide-1 receptor agonist (GLP-1 RA) and sodium-glucose cotransporter-2 (SGLT2) inhibitors are recommended for type 2 diabetes management in people at high cardiovascular (CV) risk. Their CV benefit has been documented in cardiovascular outcome trials that included mostly people in secondary CVD prevention when most people with type 2 diabetes in clinical practice are in primary CVD prevention. This presentation summarized the evidence about GLP-1 RA and SGLT2i for CVD prevention in type 2 diabetes.
About the speaker: Dr. Guillaume Grenet completed his MD specializing in endocrinology and his PhD in clinical pharmacology at the University of Lyon 1. He was a hospital doctor at the pharmaco-toxicology department of the University Hospital of Lyon. Dr. Grenet joined the Therapeutics Initiative team in September 2023, initially as a Visiting Scientist, now as a Research Associate. He is actively involved in the activities of the Drug Assessment Working Group, the Cochrane Hypertension Group and the Education Working Group of the Therapeutics Initiative. His research focuses on treatment evaluation, especially of drugs used in diabetes, metabolic diseases and cardiovascular risk factors, mostly using evidence synthesis approaches.
CME CREDITS: The Division of Continuing Professional Development, University of British Columbia Faculty of Medicine (UBC CPD) is fully accredited by the Continuing Medical Education Accreditation Committee (CACME) to provide CPD credits for physicians. This activity meets the certification criteria of the College of Family Physicians of Canada and has been certified by UBC CPD for up to 1.0 Mainpro+ Certified Activity credit. Each physician should claim only those credits accrued through participation in the activity.
No Comments